

National Imaging Associates, Inc.*	
Clinical guidelines LOW-DOSE CT FOR LUNG CANCER SCREENING	Original Date: January 2015
CPT Codes: 71271	Last Revised Date: April March 2021
Guideline Number: NIA_CG_020-1	Implementation Date: January 2023 2

INDICATIONS FOR LOW-DOSE CT (LDCT) FOR LUNG CANCER SCREENING

For Annual Lung Cancer Screening:

The use of low-dose, non-contrast spiral (helical) multi-detector CT imaging as a screening technique for lung cancer is considered **medically necessary ONLY** when used to screen for lung cancer for certain high-risk, **asymptomatic** individuals, i.e., no acute lung-related symptoms, when **ALL** of the following criteria are met¹ ~~(USPSTF, 2021)~~:

Group 1:

- Individual is between 50-80 years of age*; AND
- There is at least a 20 pack-year history of cigarette smoking; AND
- If the individual is a former smoker, that individual had quit smoking within the previous 15 years.

*May approve for individuals over the age limit if the individual is a candidate for and willing to undergo curative treatment

Group 2:

Yearly Low-Dose CT surveillance after completion of definitive treatment of non-small cell lung cancer as per these parameters² ~~(NCCN version 4.2021)~~:

- Stage I-II (treated with surgery +/- chemotherapy)
 - starts at year 2-3 of surveillance~~3~~
- Stage I-II (treated primarily with radiation) or stage III-IV with all sites treated with definitive intent
 - starts at year 5 of surveillance

* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

1—CT Lung CA Screening

©2019-202~~2~~ National Imaging Associates, Inc., All Rights Reserved

Nodule on initial LDCT (Follow-up low dose CT is approvable)³:

~~(Wood, 2018)~~

- [Table 1](#) shows the follow-up interval at which LDCT can be approved to reduce radiation dose⁴ ~~(ACR, 2019)~~
- If multiple nodules, the largest and type is used for decision

Table 1: Lung-RADS® Assessment Categories⁴ (ACR, 2019)

Category Descriptor	Lung-RADS Score	Findings	Management
Incomplete	0	Prior chest CT examination(s) being located for comparison Part or all of lungs cannot be evaluated	Additional lung cancer screening CT images and/or comparison to prior chest CT examinations is needed
Negative No nodules and definitely benign nodules	1	No lung nodules Nodule(s) with specific calcifications: complete, central, popcorn, concentric rings and fat containing nodules	Continue annual screening with LDCT in 12 months
Benign Appearance or Behavior Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth	2	Perifissural nodule(s) (See Footnote 11) < 10 mm (524 mm ³)	
		Solid nodule(s): < 6 mm (< 113 mm ³) new < 4 mm (< 34 mm ³)	
		Part solid nodule(s): < 6 mm total diameter (< 113 mm ³) on baseline screening	
		Non solid nodule(s) (GGN): < 30 mm (< 14137 mm ³) OR ≥ 30 mm (≥ 14137 mm ³) and unchanged or slowly growing	
		Category 3 or 4 nodules unchanged for ≥ 3 months	
Probably Benign Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer	3	Solid nodule(s): ≥ 6 to < 8 mm (≥ 113 to < 268 mm ³) at baseline OR new 4 mm to < 6 mm (34 to < 113 mm ³) Part solid nodule(s) ≥ 6 mm total diameter (≥ 113 mm ³) with solid component < 6 mm (< 113 mm ³) OR new < 6 mm total diameter (< 113 mm ³) Non solid nodule(s) (GGN) ≥ 30 mm (≥ 14137 mm ³) on baseline CT or new	6 month LDCT
Suspicious Findings for which additional diagnostic testing is recommended	4A	Solid nodule(s): ≥ 8 to < 15 mm (≥ 268 to < 1767 mm ³) at baseline OR growing < 8 mm (< 268 mm ³) OR new 6 to < 8 mm (113 to < 268 mm ³) Part solid nodule(s): ≥ 6 mm (≥ 113 mm ³) with solid component ≥ 6 mm to < 8 mm (≥ 113 to < 268 mm ³) OR with a new or growing < 4 mm (< 34 mm ³) solid component Endobronchial nodule	3 month LDCT; PET/CT may be used when there is a ≥ 8 mm (≥ 268 mm ³) solid component
Very Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended	4B	Solid nodule(s) ≥ 15 mm (≥ 1767 mm ³) OR new or growing, and ≥ 8 mm (≥ 268 mm ³) Part solid nodule(s) with: a solid component ≥ 8 mm (≥ 268 mm ³) OR a new or growing ≥ 4 mm (≥ 34 mm ³) solid component	Chest CT with or without contrast, PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities. PET/CT may be used when there is a ≥ 8 mm (≥ 268 mm ³) solid component. For new large nodules that develop on an annual repeat screening CT, a 1 month LDCT may be recommended to address potentially infectious or inflammatory conditions
	4X	Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy	
Other Clinically Significant or Potentially Clinically Significant Findings (non lung cancer)	S	Modifier - may add on to category 0-4 coding	As appropriate to the specific finding

BACKGROUND

Smoking-related lung cancer is the leading cause of cancer deaths in both men and women in the United States. Treatment for most lung cancer is focused on surgery which is usually curative only when the tumors are very small. Screening for early lung cancer with sputum cytology and chest x-rays has not been successful in reducing deaths from lung cancer. However, in 2011, a large, prospective, multicenter trial was published that showed CT Chest screening identified early cancers better than other approaches and reduced the death rate from lung cancer. In 2014, the United States Preventive Service Task Force (USPSTF) recommended annual low-dose CT Chest screening (CPT® code 71271) for people with current or recent past smoking histories.

All screening and follow-up chest CT scans to be performed at low dose (100-120 kVp and 40-60 mAs), unless evaluating mediastinal findings or lymph nodes, where standard dose CT with IV contrast may be more appropriate ~~(NCCN, 2021)~~.²

OVERVIEW

Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.

POLICY HISTORY

Date	Summary
March 2022	Reviewed data. No significant updates since prior revision.
April 2021	<ul style="list-style-type: none">Added data about expanding screening to older patients that are willing to have and that are candidates for definitive treatment for lung cancer, based on NCCN recommendationsAdded long term surveillance in patients who received definitive treatment for non small cell lung cancer
March 10, 2021	<ul style="list-style-type: none">Eliminated groupings (group 1 and group 2) for lung cancer screening and changed age of 55-80 years to 50-80 years; changed to 20 pack year history of cigarette smoking and requirement of additional risk factors (USPSTF 2021)
November 9, 2020	<ul style="list-style-type: none">Replaced CPT code G0297 with 71271
May 2020	<ul style="list-style-type: none">Lung Cancer Screening:<ul style="list-style-type: none">Changed upper age limit from 77 to 80 yrs oldAdded:<ul style="list-style-type: none">Age ≥ 50 years old; AND≥ 20 pack-year history of smoking; ANDAdditional risk factors (other than second-hand smoke)*

	<p><i>*Additional risk factors include: Survivors of lung cancer, lymphoma, cancers of the head and neck and bladder (smoking related cancers), first degree family members with a history of lung cancer, history of COPD or pulmonary fibrosis, radon exposure, retinoblastoma, Li Fraumeni syndrome, occupational exposure to arsenic, chromium, asbestos, nickel, cadmium, beryllium, silica, diesel fumes, coal smoke and soot</i></p> <ul style="list-style-type: none"> • Updated the follow-up interval for LDCT information, using the ACR 2019 Lung RADS chart • Updated background information
May 2019	<ul style="list-style-type: none"> • Criteria for repeating at less than one year were added. • Upper age range changed from 80 to 77 years of age • Chart added for the f/u interval at which LDCT can be approved to reduce radiation dose

REFERENCES

~~American College of Radiology (ACR). Lung RADS Assessment Categories v1.1. 2019.
<https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads>.~~

~~Mazzone PJ, Silvestri GA, Patel S, et al. Screening for lung cancer CHEST guideline and expert panel report. *Chest*. 2018; 153(4):954-985.~~

~~National Comprehensive Cancer Network (NCCN). *NCCN Guidelines Version 4.2021—Non-Small Cell Lung Cancer*. March 3, 2021.
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.~~

~~U.S. Preventive Services Task Force (USPSTF). Lung Cancer: Screening. Final recommendation statement, March 9, 2021.
<https://uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening>.~~

~~Wood DE, Kazerooni EA, Baum SL, et al. Clinical practice guidelines in oncology: Lung cancer screening. Version 3.2018. *J Natl Compr Canc Netw*. 2018; 16(4):412-441.~~

~~Reviewed / Approved by NIA Clinical Guideline Committee~~

GENERAL INFORMATION

~~It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.~~

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

1. Final Recommendation Statement Lung Cancer: Screening U.S. Preventive Services Task Force (USPSTF). Updated March 9, 2021. Accessed November 16, 2021. <https://uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening>
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer Version 1.2022. National Comprehensive Cancer Network (NCCN). Updated December 7, 2021. Accessed February 17, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
3. Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. Apr 2018;16(4):412-441. doi:10.6004/jnccn.2018.0020
4. Lung-RADS® Version 1.1. American College of Radiology (ACR). Updated 2019. Accessed November 16, 2021. <https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf>

ADDITIONAL RESOURCE(S)

1. Mazzone PJ, Silvestri GA, Patel S, et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. *Chest*. Apr 2018;153(4):954-985. doi:10.1016/j.chest.2018.01.016

Reviewed / Approved by NIA Clinical Guideline Committee

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.